文献速递围术期管理与 ERAS急腹症与外科感染

病例抽样与全面审查评估美国外科质量改进项目中医院术后死亡率的比较

Case Sampling vs Universal Review for Evaluating Hospital Postoperative Mortality in US Surgical Quality Improvement Programs.
PubMed 文献 · JAMA Surg · 2023-01-01

该研究基于美国退伍军人事务部113家医院2016年1月1日至2020年9月30日的非心脏手术数据,比较代表性抽样(502953例)与全面审查(1703140例)对30天死亡率的评估效果。抽样与全面审查队列30天死亡率分别为0.8%和0.6%(P<.001),抽样仅识别出不到一半的术后死亡率高于预期的医院。

要点

  • 抽样队列30天死亡率为0.8%,全面审查队列为0.6%,差异有统计学意义(P<.001)。
  • 在2145个医院季度中,抽样识别异常医院的比例为11.7%,全面审查为13.2%。
  • 抽样识别的异常医院季度中仅47.4%被全面审查同时识别,全面审查识别的仅42.1%被抽样同时识别。

核心结论

  • 全国外科质量改进项目采用的抽样策略仅识别出不到一半的术后死亡率高于预期的医院,抽样可能无法充分代表整体外科项目表现或为利益相关者提供质量改进所需数据。

研究设计与样本

  • 比较效果研究,为全国性医院层面分析,纳入2016年1月1日至2020年9月30日在美国退伍军人事务部医院接受非心脏手术的成年患者(年龄≥18岁),数据来自退伍军人事务部外科质量改进项目(代表性样本)和退伍军人事务部企业数据仓库手术域(100%手术病例),数据分析于2022年7月1日至12月21日进行。

主要发现

  • 研究纳入113家美国退伍军人事务部医院,抽样队列包含502953例手术病例,全面审查队列包含1703140例。
  • 抽样队列和全面审查队列中大多数患者为男性(90.2% vs 91.1%)和白人(74.7% vs 74.5%)。
  • 总体30天死亡率在抽样队列为0.8%,在全面审查队列为0.6%(P<.001)。
  • 在2145个医院季度数据中,抽样识别异常医院的季度比例为11.7%,全面审查为13.2%。
  • 仅抽样识别的异常医院平均季度30天死亡率为0.4%,仅全面审查识别的为0.8%,两者同时识别的为0.9%;未抽样病例中,异常医院平均季度30天死亡率为1.0%,非异常医院为0.5%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Representative surgical case sampling, rather than universal review, is used by US Department of Veterans Affairs (VA) and private-sector national surgical quality improvement (QI) programs to assess program performance and to inform local QI and performance improvement efforts. However, it is unclear whether case sampling is robust for identifying hospitals with safety or quality concerns. OBJECTIVE: To evaluate whether the sampling strategy used by several national surgical QI programs provides hospitals with data that are representative of their overall quality and safety, as measured by 30-day mortality. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness study was a national, hospital-level analysis of data from adult patients (aged ≥18 years) who underwent noncardiac surgery at a VA hospital between January 1, 2016, and September 30, 2020. Data were obtained from the VA Surgical Quality Improvement Program (representative sample) and the VA Corporate Data Warehouse surgical domain (100% of surgical cases). Data analysis was performed from July 1 to December 21, 2022. MAIN OUTCOMES AND MEASURES: The primary outcome was postoperative 30-day mortality. Quarterly, risk-adjusted, 30-day mortality observed-to-expected (O-E) ratios were calculated separately for each hospital using the sample and universal review cohorts. Outlier hospitals (ie, those with higher-than-expected mortality) were identified using an O-E ratio significantly greater than 1.0. RESULTS: In this study of data from 113 US Department of Veterans Affairs hospitals, the sample cohort comprised 502 953 surgical cases and the universal review cohort comprised 1 703 140. The majority of patients in both the representative sample and the universal sample were men (90.2% vs 91.1%) and were White (74.7% vs 74.5%). Overall, 30-day mortality was 0.8% and 0.6% for the sample and universal review cohorts, respectively (P < .001). Over 2145 quarters of data, hospitals were identified as an outlier in 11.7% of quarters with sampling and in 13.2% with universal review. Average hospital quarterly 30-day mortality rates were 0.4%, 0.8%, and 0.9% for outlier hospitals identified using the sample only, universal review only, and concurrent identification in both data sources, respectively. For nonsampled cases, average hospital quarterly 30-day mortality rates were 1.0% at outlier hospitals and 0.5% at nonoutliers. Among outlier hospital quarters in the sample, 47.4% were concurrently identified with universal review. For those identified with universal review, 42.1% were concurrently identified using the sample. CONCLUSIONS AND RELEVANCE: In this national, hospital-level study, sampling strategies employed by national surgical QI programs identified less than half of hospitals with higher-than-expected perioperative mortality. These findings suggest that sampling may not adequately represent overall surgical program performance or provide stakeholders with the data necessary to inform QI efforts.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Chen VW, Chidi AP, Rosen T, et al. Case Sampling vs Universal Review for Evaluating Hospital Postoperative Mortality in US Surgical Quality Improvement Programs. JAMA Surg. 2023. PMID: 37755869. doi:10.1001/jamasurg.2023.4532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。